Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial
Benjamin Besse1, Jessica J Lin2, Lyudmila Bazhenova3
1Paris-Saclay University, Gustave Roussy Cancer Center, Villejuif, France. Benjamin.BESSE@gustaveroussy.fr.
Nature Medicine
|February 4, 2026
Summary
Repotrectinib, a next-generation tyrosine kinase inhibitor (TKI), shows durable responses in NTRK fusion-positive solid tumors. This TKI is effective even in patients previously treated with TKIs and those with specific mutations, demonstrating a favorable safety profile.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Early-generation TRK tyrosine kinase inhibitors (TKIs) offer clinical benefits for NTRK fusion-positive (NTRK+) solid tumors but are limited by emerging resistance.
- Repotrectinib is a next-generation ROS1/TRK TKI engineered with a macrocyclic structure to enhance response durability.
Purpose of the Study:
- To assess the efficacy and safety of repotrectinib in adult patients with advanced solid tumors, specifically focusing on NTRK+ disease.
- To evaluate repotrectinib's performance in both TKI-naive and TKI-pretreated patient populations, including those with specific NTRK solvent front mutations.
Main Methods:
- The TRIDENT-1 trial (Phase 1/2, NCT03093116) evaluated repotrectinib in patients with advanced solid tumors, including NTRK+ disease.
- Primary endpoint: confirmed objective response rate. Secondary endpoints: duration of response (DOR), progression-free survival (PFS), overall survival, and safety.
- Patients were stratified into TKI-naive and TKI-pretreated cohorts, with subgroup analyses for solvent front mutations and intracranial disease.
Main Results:
- In TKI-naive patients (n=51), response rate was 59% (95% CI: 44-72) with a median PFS of 30.3 months (9.0-NE).
- In TKI-pretreated patients (n=69), response rate was 48% (95% CI: 36-60) with a median DOR of 9.8 months (7.4-13.0) and median PFS of 7.4 months (3.9-9.7).
- Of 30 TKI-pretreated patients with NTRK solvent front mutations, 16 responded (53%; 95% CI: 34-72). Intracranial responses were observed in both cohorts.
Conclusions:
- Repotrectinib demonstrated durable systemic and intracranial responses in patients with NTRK+ solid tumors, including those with prior TRK TKI treatment and solvent front mutations.
- The treatment-related adverse events were generally low-grade, with a low discontinuation rate (4%), supporting repotrectinib's favorable safety profile.
- These findings support repotrectinib as a valuable therapeutic option for patients diagnosed with NTRK fusion-positive solid tumors.
Related Concept Videos
Phase Diagrams
50.3K
A phase diagram combines plots of pressure versus temperature for the liquid-gas, solid-liquid, and solid-gas phase-transition equilibria of a substance. These diagrams indicate the physical states that exist under specific conditions of pressure and temperature and also provide the pressure dependence of the phase-transition temperatures (melting points, sublimation points, boiling points). Regions or areas labeled solid, liquid, and gas represent single phases, while lines or curves represent...
50.3K
Phase Transitions: Melting and Freezing
15.2K
Heating a crystalline solid increases the average energy of its atoms, molecules, or ions, and the solid gets hotter. At some point, the added energy becomes large enough to partially overcome the forces holding the molecules or ions of the solid in their fixed positions, and the solid begins the process of transitioning to the liquid state or melting. At this point, the temperature of the solid stops rising, despite the continual input of heat, and it remains constant until all of the solid is...
15.2K
Predicting Products: SN1 vs. SN2
17.4K
Nucleophilic substitution reactions of alkyl halides can proceed via an SN1 or an SN2 mechanism. While in SN2 reactions, the nucleophile attacks the substrate simultaneously as the leaving group departs, in SN1 reactions, the substrate first dissociates to give the carbocation intermediate. Various factors such as the structure of the substrate, the strength of the nucleophile, and the nature of the solvent promote one mechanism over the other.
With increased substitution on the alkyl halide,...
With increased substitution on the alkyl halide,...
17.4K
Nuclear Fusion
33.9K
The process of converting very light nuclei into heavier nuclei is also accompanied by the conversion of mass into large amounts of energy, a process called fusion. The principal source of energy in the sun is a net fusion reaction in which four hydrogen nuclei fuse and ultimately produce one helium nucleus and two positrons.
A helium nucleus has a mass that is 0.7% less than that of four hydrogen nuclei; this lost mass is converted into energy during the fusion. This reaction produces about...
A helium nucleus has a mass that is 0.7% less than that of four hydrogen nuclei; this lost mass is converted into energy during the fusion. This reaction produces about...
33.9K
Structures of Solids
17.9K
Solids in which the atoms, ions, or molecules are arranged in a definite repeating pattern are known as crystalline solids. Metals and ionic compounds typically form ordered, crystalline solids. A crystalline solid has a precise melting temperature because each atom or molecule of the same type is held in place with the same forces or energy. Amorphous solids or non-crystalline solids (or, sometimes, glasses) which lack an ordered internal structure and are randomly arranged. Substances that...
17.9K
Phase Transitions: Sublimation and Deposition
20.2K
Some solids can transition directly into the gaseous state, bypassing the liquid state, via a process known as sublimation. At room temperature and standard pressure, a piece of dry ice (solid CO2) sublimes, appearing to gradually disappear without ever forming any liquid. Snow and ice sublimate at temperatures below the melting point of water, a slow process that may be accelerated by winds and the reduced atmospheric pressures at high altitudes. When solid iodine is warmed, the solid sublimes...
20.2K


![Solid-phase Synthesis of [4.4] Spirocyclic Oximes](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58508.jpg&w=3840&q=50)